Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target and the rates of infection were higher with secuk inumab than with placebo in both studies and were similar to those with etanercept.
Global epidemiology of psoriasis: a systematic review of incidence and prevalence.
- R. Parisi, D. Symmons, C. Griffiths, D. Ashcroft
- MedicineThe Journal of investigative dermatology
- 1 February 2013
The data indicated that the occurrence of psoriasis varied according to age and geographic region, being more frequent in countries more distant from the equator and trends in incidence over time.
Psoriasis: epidemiology, clinical features, and quality of life
The epidemiology, clinical features, and impact on quality of life of psoriasis are reviewed.
European S3‐Guidelines on the systemic treatment of psoriasis vulgaris
- D. Pathirana, A. Ormerod, B. Rzany
- MedicineJournal of the European Academy of Dermatology…
- 1 October 2009
Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris and has a good cost-benefit ratio, but the potentially significant costs for, and time required of, the patient must be considered.
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
Pathogenesis and clinical features of psoriasis
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-week period in patients with psoriasis.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the…
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
Background In previous studies, etanercept significantly improved plaque psoriasis and was well tolerated and a well tolerated drug.